Treatment and outcomes in patients with chronic myeloid leukemia treated first line therapy with Imatinib and with second generation tyrosine kinase inhibitors:EUTOS population-based registry

Trial Profile

Treatment and outcomes in patients with chronic myeloid leukemia treated first line therapy with Imatinib and with second generation tyrosine kinase inhibitors:EUTOS population-based registry

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Dasatinib (Primary) ; Imatinib (Primary) ; Nilotinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms EUTOS
  • Most Recent Events

    • 28 Jul 2017 Results published in the Internet Document
    • 23 Sep 2016 Study was terminated in 2012 due to different regulatory requirements in the participating countries.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top